Milan, Italy – December 23, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy – October 21, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Milan, Italy – September 22, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients
Milan, Italy – September 15, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a research and development company focused on novel Central Nervous System (CNS) and pain
Zambon today announces the availability of Xadago® (safinamide) in Norway as an add-on to levodopa alone or in combination with other Parkinson’s disease (PD) medications
Milan, Italy – July 26, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
